Clinical trial · Observational
Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1
Le Traitement Par Lenvatinib + Anti-PD1 Du Mélanome Métastatique
NCT06586580CI-TRIAL-00080527LENVAMELcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The hypothesis is that treatment with Lenvatinib + Pembrolizumab is less effective in real life than in clinical trials. In fact, an objective response rate \< 20% and a worse tolerability of the treatment in real life with ≥50% of severe toxicities are expected.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Melanoma | Melanoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Metastatic melanoma
- description
- Metastatic melanoma refractory to immunotherapy
Primary outcomes (1)
- measure
- Objective response rate
- timeFrame
- Month 18
Secondary outcomes (3)
- measure
- Progression-free survival
- timeFrame
- Month 18
- measure
- Overall survival
- timeFrame
- Month 18
- measure
- Frequencies of severe toxicities leading to treatment interruption
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Metastatic melanoma (stage III non operable or stage IV according to American Joint Committee on Cancer staging rules) refractory to immunotherapy (≥ 2nd treatment line after minimum a failure of immunotherapy) Exclusion Criteria: * Uveal melanoma
References
Publications (0)
Data not yet available
No reference posted for this study.